查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1609137

發作性睡病治療藥物市場：按類型、治療藥物類型 - 全球預測 2025-2030

Narcolepsy Drugs Market by Type (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy), Therapeutics Type (Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年發作性睡病治療藥物市場價值為30.5億美元，預計到2024年將達到32.8億美元，複合年成長率為6.77%，到2030年將達到48.3億美元。

發作性睡病藥物是針對慢性神經系統疾病的標靶治療，這些疾病患者無法調節睡眠-覺醒週期，導致白天過度嗜睡、猝倒和夜間睡眠障礙。對這些藥物的需求源於人們對發作性睡病對生活品質影響的認知的提高以及對有效管理策略的需要。它的用途各不相同，包括用於解決白天嗜睡的興奮劑、用於控制猝倒的抗憂鬱症以及用於解決多種症狀的羥丁酸鈉。最終用途範圍涵蓋醫院、診所和居家照護等醫療保健環境，重點是個人化護理。發作性睡病藥物市場的關鍵成長要素包括診斷病例數量的增加、改善藥物傳遞的技術進步以及醫療保健成本的上升。副作用較少的新治療方法的開發正在被推動，透過個人化醫療和生物技術的創新，潛在的商機正在擴大。持續的監管支援以及人工智慧在藥物開發研究中的整合進一步強化了市場格局。阻礙成長的挑戰包括高昂的藥品成本、潛在的副作用、低度開發地區的意識低下以及減緩新治療方法推出的嚴格監管障礙。非侵入性藥物傳遞系統（例如經皮吸收貼片）以及了解發作性睡病遺傳傾向的研究還有創新開拓。公司應專注於策略聯盟、廣泛的臨床試驗和強力的定價策略，以實現可負擔性。市場是動態的，需要適應快速的科學進步和不斷變化的消費者態度，要求相關人員保持敏捷和知情。透過教育宣傳活動和與監管機構的合作解決限制可以幫助最佳化繁瑣的路線並提高產品的可及性和更廣泛的接受度。隨著市場的發展，結合永續實踐和數位健康整合可以為公司提供可行的見解和競爭優勢。

主要市場統計
基準年[2023] 30.5億美元
預計年份 [2024] 32.8億美元
預測年份 [2030] 48.3億美元
複合年成長率（%） 6.77%

市場動態：快速發展的發作性睡病藥物市場的關鍵市場洞察

供給和需求的動態交互作用正在改變發作性睡病藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 發作性睡病患病率增加
    • 提高消費者對發作性睡病藥物益處的認知
    • 睡眠相關疾病的醫療支出增加
  • 市場限制因素
    • 發作性睡病藥物的副作用
  • 市場機會
    • 政府努力開發治療發作性睡病的藥物
    • 開發新藥的持續研究開發活動
  • 市場挑戰
    • 對新興經濟體的滲透延遲

波特的五力：駕馭發作性睡病藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解發作性睡病藥物市場的外部影響

外部宏觀環境因素在塑造發作性睡病治療藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解發作性睡病治療藥物市場的競爭狀況

發作性睡病治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣發作性睡病治療市場供應商的績效評估

FPNV 定位矩陣是評估發作性睡病治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為發作性睡病治療藥物市場的成功指明道路

發作性睡病治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 發作性睡病患病率增加
      • 提高消費者對發作性睡病藥物益處的認知
      • 睡眠相關疾病的醫療費用增加
    • 抑制因素
      • 發作性睡病藥物的副作用
    • 機會
      • 政府努力開發治療發作性睡病的藥物
      • 開發新藥的持續研究和開發活動
    • 任務
      • 新興經濟體滲透率低
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章發作性睡病治療藥物市場：依類型

  • 發作性睡病和猝倒症
  • 不伴猝倒的發作性睡病
  • 次發性睡病

第7章發作性睡病治療藥物市場（依治療藥物類型）

  • 中樞神經系統興奮劑
  • 選擇性血清素再回收抑制劑
  • 羥丁酸鈉
  • 三環抗憂鬱藥物

第8章美洲發作性睡病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區發作性睡病治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的發作性睡病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Avadel Pharmaceuticals Plc
  • Axsome Therapeutics Inc.
  • Cadila Pharmaceuticals Ltd.
  • Don Valley Pharmaceuticals
  • Graymark Healthcare Inc.
  • Jabs Biotech Pvt. Ltd.
  • Jazz Pharmaceuticals PLC
  • Luckys Pharma Pvt. Ltd.
  • Midas Pharma GmbH
  • Orbion Pharmaceuticals Pvt. Ltd.
  • Shionogi and Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • XWPharma Ltd.
Product Code: MRR-62667ADF9625

The Narcolepsy Drugs Market was valued at USD 3.05 billion in 2023, expected to reach USD 3.28 billion in 2024, and is projected to grow at a CAGR of 6.77%, to USD 4.83 billion by 2030.

Narcolepsy drugs are targeted treatments for a chronic neurological disorder characterized by an inability to regulate sleep-wake cycles, resulting in excessive daytime sleepiness, cataplexy, and disturbed nocturnal sleep. The necessity for these drugs arises from the growing awareness of narcolepsy's impact on the quality of life, necessitating effective management strategies. Their applications vary, including stimulants for combating daytime lethargy, antidepressants for controlling cataplexy, and sodium oxybate for addressing multiple symptoms. The end-use scope ranges across healthcare settings like hospitals, clinics, and homecare, emphasizing personalized care. Key growth influencers in the narcolepsy drug market include a rise in diagnosed cases, advancements in technology for better drug delivery, and increased healthcare expenditure. There's a push towards developing novel therapies with fewer side effects, opening potential opportunities in personalized medicine and biotech innovations. Continuous regulatory support and integration of artificial intelligence in research for drug development further enhance the market landscape. Challenges hindering growth include the high cost of drugs, potential side effects, limited awareness in underdeveloped regions, and stringent regulatory hurdles that delay the introduction of new therapies. Innovating with non-invasive drug delivery systems, such as transdermal patches, and furthering research into understanding genetic predispositions in narcolepsy are avenues ripe for exploration. Companies should focus on strategic alliances, expansive clinical trials, and robust pricing strategies to enhance affordability. The market is dynamic, necessitating adaptability to rapid scientific advancements and shifts in consumer awareness, requiring stakeholders to remain agile and informed. Addressing limitations through education campaigns and collaboration with regulatory entities can optimize onerous pathways, enhancing product accessibility and fostering broader acceptance. As the market evolves, embracing sustainable practices and digital health integration could provide businesses with actionable insights and a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 3.05 billion
Estimated Year [2024] USD 3.28 billion
Forecast Year [2030] USD 4.83 billion
CAGR (%) 6.77%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Narcolepsy Drugs Market

The Narcolepsy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of narcolepsy disorder
    • Growing consumer awareness towards benefits of narcolepsy drugs
    • Rising healthcare spending for sleep related disorders
  • Market Restraints
    • Side effects of narcolepsy drugs
  • Market Opportunities
    • Governmental initiatives for narcolepsy drug development
    • Ongoing research and development activities for novel drug development
  • Market Challenges
    • Less penetration across developing economies

Porter's Five Forces: A Strategic Tool for Navigating the Narcolepsy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Narcolepsy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Narcolepsy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Narcolepsy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Narcolepsy Drugs Market

A detailed market share analysis in the Narcolepsy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Narcolepsy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Narcolepsy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Narcolepsy Drugs Market

A strategic analysis of the Narcolepsy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Narcolepsy Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals Plc, Axsome Therapeutics Inc., Cadila Pharmaceuticals Ltd., Don Valley Pharmaceuticals, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals PLC, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., Shionogi and Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd..

Market Segmentation & Coverage

This research report categorizes the Narcolepsy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy.
  • Based on Therapeutics Type, market is studied across Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate, and Tricyclic Antidepressants.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of narcolepsy disorder
      • 5.1.1.2. Growing consumer awareness towards benefits of narcolepsy drugs
      • 5.1.1.3. Rising healthcare spending for sleep related disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects of narcolepsy drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Governmental initiatives for narcolepsy drug development
      • 5.1.3.2. Ongoing research and development activities for novel drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Less penetration across developing economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Narcolepsy Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Narcolepsy with Cataplexy
  • 6.3. Narcolepsy without Cataplexy
  • 6.4. Secondary Narcolepsy

7. Narcolepsy Drugs Market, by Therapeutics Type

  • 7.1. Introduction
  • 7.2. Central Nervous System Stimulants
  • 7.3. Selective Serotonin Reuptake Inhibitor
  • 7.4. Sodium Oxybate
  • 7.5. Tricyclic Antidepressants

8. Americas Narcolepsy Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Narcolepsy Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Narcolepsy Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Aurobindo Pharma Ltd.
  • 3. Avadel Pharmaceuticals Plc
  • 4. Axsome Therapeutics Inc.
  • 5. Cadila Pharmaceuticals Ltd.
  • 6. Don Valley Pharmaceuticals
  • 7. Graymark Healthcare Inc.
  • 8. Jabs Biotech Pvt. Ltd.
  • 9. Jazz Pharmaceuticals PLC
  • 10. Luckys Pharma Pvt. Ltd.
  • 11. Midas Pharma GmbH
  • 12. Orbion Pharmaceuticals Pvt. Ltd.
  • 13. Shionogi and Co. Ltd.
  • 14. Takeda Pharmaceutical Co. Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. XWPharma Ltd.

LIST OF FIGURES

  • FIGURE 1. NARCOLEPSY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. NARCOLEPSY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. NARCOLEPSY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. NARCOLEPSY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NARCOLEPSY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NARCOLEPSY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY NARCOLEPSY WITH CATAPLEXY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY NARCOLEPSY WITHOUT CATAPLEXY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SECONDARY NARCOLEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SODIUM OXYBATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NARCOLEPSY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. NARCOLEPSY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023